Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial
Authors' conclusion
In the OCEAN(a)-DOSE multicenter randomized clinical trial, olpasiran led to a significant and sustained reduction in OxPL-apoB but no significant effects on hs-CRP or hs-IL-6.
Study context
- Population
- Patients with atherosclerotic CVD and Lp(a) >150 nmol/L272 analysed
- Participants
- 281 patients
- Comparison
- Olpasiran vs placebo
- Primary endpoint
- Placebo-adjusted change in OxPL-apoB
- Follow-up
- Baseline to week 36
Methodological detailsinternational, multicentre, placebo-controlled, phase 2, dose-finding, Conducted July 2020 to November 2022
- International
- Multicentre
- Placebo-controlled
- Phase 2
- Dose-finding
- Conducted July 2020 to November 2022
Primary result
As reported in the abstract
Placebo-adjusted mean % change in OxPL-apoB · week 36
Each group vs placeboPlacebo-adjusted mean percentage change, % (95% CI)P value
10 mg Q12W
−51.6(−64.9% to −38.2%)
P < 0.00175 mg Q12W
−89.7(−103.0% to −76.4%)
P < 0.001225 mg Q12W
−92.3(−105.6% to −78.9%)
P < 0.001225 mg Q24W
−93.7(−107.1% to −80.3%)
P < 0.001Further findings
| Outcome | Placebo-adjusted percentage change (%) | P value |
|---|---|---|
| Placebo-adjusted % change in OxPL-apoB · week 4810 mg Q12W vs Placebo | −50.8 | P < 0.001 |
| Placebo-adjusted % change in OxPL-apoB · week 4875 mg Q12W vs Placebo | −100.2 | P < 0.001 |
| Placebo-adjusted % change in OxPL-apoB · week 48225 mg Q12W vs Placebo | −104.7 | P < 0.001 |
| Placebo-adjusted % change in OxPL-apoB · week 48225 mg Q24W vs Placebo | −85.8 | P < 0.001 |
Correlation of % reduction in Lp(a) and OxPL on apolipoprotein B (OxPL-apoB) (olpasiran)
- Strong correlation, r
- 0.79
- P
- P < 0.001
Hs-C-reactive protein (hs-CRP) and hs-IL-6 · weeks 36 or 48
- No significant impact of olpasiran vs placebo
- P > 0.05
Original publication
Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial. JAMA Cardiol. Published 1 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →